Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Asterias Biotherapeutics, Inc.AST · Entity 159180 | Director | June 21, 2018 | June 25, 2018 |
| COMARCO INCCMRO · Entity 173122 | Director | October 27, 2016 | October 31, 2016 |
| STAAR SURGICAL COSTAA · Entity 4851 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Asterias Biotherapeutics, Inc.
Report date June 21, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-21 | Direct | 20,000 |
Reported balance
After 2018-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-21 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2026-02-28 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 20,000 |
| Series A Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 25,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2027-03-29 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 20,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2020-03-31 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 20,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2019-03-31 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 20,000 |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $4.37 · Expires 2021-05-13 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 7,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors.
COMARCO INC
Report date October 27, 2016 · Filed October 31, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Right to buySEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2025-06-17 | Direct | 50,000 |
Reported balance
After 2016-10-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-27 · Grant · Acquired 24,047 · Balance 50,000 F1: On June 17, 2015, the Reporting Person received 25,953 out of a total of 50,000 board approved options, as there were insufficient shares then available under the Issuer's 2011 Equity Incentive Plan and the remaining 24,047 options were granted subject to an increase in shares under the 2011 Equity Plan. As an increase in shares under the 2011 Equity Plan was recently approved at the Company's 2016 Annual Shareholders Meeting, this grant represents the balance of the June 17, 2015 award with the same vesting and expiration dates as the original 25,953 option grant on June 17, 2015. |
| Right to buySEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2026-10-27 | Direct | 50,000 |
Reported balance
After 2016-10-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-27 · Grant · Acquired 50,000 · Balance 50,000 F2: The Reporting Person received a grant of stock options pursuant to the Issuer's 2011 Equity Incentive Plan. The option shall vest in full on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 17, 2015, the Reporting Person received 25,953 out of a total of 50,000 board approved options, as there were insufficient shares then available under the Issuer's 2011 Equity Incentive Plan and the remaining 24,047 options were granted subject to an increase in shares under the 2011 Equity Plan. As an increase in shares under the 2011 Equity Plan was recently approved at the Company's 2016 Annual Shareholders Meeting, this grant represents the balance of the June 17, 2015 award with the same vesting and expiration dates as the original 25,953 option grant on June 17, 2015.
F2: The Reporting Person received a grant of stock options pursuant to the Issuer's 2011 Equity Incentive Plan. The option shall vest in full on the one-year anniversary of the grant date.
STAAR SURGICAL CO
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OPTION TO PURCHASE COMMON STOCKSEC Table II · derivative / convertible security · Conversion / exercise price $29.12 · Expires 2036-06-18 | Direct | 11,145 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 11,145 · Balance 11,145 F2: These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended. F1: These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer. |
| OPTION TO PURCHASE COMMON STOCKSEC Table II · derivative / convertible security · Conversion / exercise price $18.46 · Expires 2036-03-05 | Direct | 7,524 |
Reported balance
Holding disclosure · report date 2026-06-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 7,524 F3: These options are currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer.
F2: These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.
F3: These options are currently exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 23:40 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantOPTION TO PURCHASE COMMON STOCK · Derivative | 11,145 | $0.00 Strike: $29.12 | $0.00 |
DisclosureSEC source: 0000919574-26-004069 · ownership.xml · derivative · entry 1 LeBuhn Richard T. · CIK 0001428664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,145 Underlying: COMMON STOCK · 11,145 shares Expires 2036-06-18 F2 · price: These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 23:05 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantOPTION TO PURCHASE COMMON STOCK · Derivative | 7,524 | $0.00 Strike: $18.46 | $0.00 |
DisclosureSEC source: 0000919574-26-001545 · ownership.xml · derivative · entry 1 LeBuhn Richard T. · CIK 0001428664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,524 Underlying: COMMON STOCK · 7,524 shares Expires 2036-03-05 F2 · price: These options were granted to the Reporting Person by the Issuer on March 6, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: These options will vest and become exercisable on the earlier of: (a) June 18, 2026 and (b) the date of STAAR Surgical Company's (the "Issuer") 2026 annual meeting of shareholders, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:47 UTC | Asterias Biotherapeutics, Inc. AST · Entity 159180 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-18-029807 · form4.xml · derivative · entry 2 LeBuhn Richard T. · CIK 0001428664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 20:58 UTC | Asterias Biotherapeutics, Inc. AST · Entity 159180 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001140361-17-014402 · form4.xml · derivative · entry 1 LeBuhn Richard T. · CIK 0001428664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-29 F1 · security: The stock options vest over four equal quarterly installments beginning on March 31, 2017, contingent upon continued service on the Board of Directors. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 18:58 UTC | COMARCO INC CMRO · Entity 173122 | GrantRight to buy · Derivative | 50,000 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001437749-16-040677 · rdgdoc.xml · derivative · entry 2 LeBuhn Richard T. · CIK 0001428664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-10-27 F2 · security: The Reporting Person received a grant of stock options pursuant to the Issuer's 2011 Equity Incentive Plan. The option shall vest in full on the one-year anniversary of the grant date. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 18:58 UTC | COMARCO INC CMRO · Entity 173122 | GrantRight to buy · Derivative | 24,047 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001437749-16-040677 · rdgdoc.xml · derivative · entry 1 LeBuhn Richard T. · CIK 0001428664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 24,047 shares Expires 2025-06-17 F1 · security: On June 17, 2015, the Reporting Person received 25,953 out of a total of 50,000 board approved options, as there were insufficient shares then available under the Issuer's 2011 Equity Incentive Plan and the remaining 24,047 options were granted subject to an increase in shares under the 2011 Equity Plan. As an increase in shares under the 2011 Equity Plan was recently approved at the Company's 2016 Annual Shareholders Meeting, this grant represents the balance of the June 17, 2015 award with the same vesting and expiration dates as the original 25,953 option grant on June 17, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.